Sanofi ADR (SNY)

Currency in USD
46.78
-0.75(-1.58%)
Closed·
46.85+0.07(+0.15%)
·

SNY Earnings

Latest Release
Apr 23, 2026
EPS / Forecast
2.17 / 1.79
Revenue / Forecast
12.14B / 10.25B
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
2026/06--/1.09--/13.17B----Free Sign Up
2026/032.17/1.7912.14B/10.25B+21.23%+18.44%Free Sign Up
2025/121.80/0.84013.27B/13.58B+114.29%-2.28%Free Sign Up
2025/091.69/1.5815.31B/15.00B+6.96%+2.07%Free Sign Up
2025/061.59/0.9599.99B/11.97B+65.76%-16.54%Free Sign Up
2025/030.785/1.6712.06B/10.99B-53.01%+9.74%Free Sign Up
2024/121.31/0.78010.56B/12.38B+67.95%-14.7%Free Sign Up
2024/092.25/1.3713.44B/14.26B+64.23%-5.75%Free Sign Up
2024/061.73/0.89010.74B/11.68B+94.38%-8.05%Free Sign Up
2024/031.78/0.93010.46B/11.47B+91.4%-8.81%Free Sign Up

All numbers in USD

Sanofi ADR Earnings Call Summary for Q1/2026

  • Sanofi Q1 2026 EPS of $2.17 beat forecast of $1.79 by 21%; revenue reached $12.14B vs. expected $10.25B, driving 3.39% premarket stock gain.
  • Revenue grew 13.6% YoY at constant rates, led by Dupixent sales of €4.2B and contributions from Blueprint and Dynavax acquisitions.
  • Operating expenses rose 7% but declined 1.9 percentage points as share of sales, demonstrating improved operational leverage and cost management.
  • Company projects FY2026 EPS of $9.92 and revenue of $54.45B; FY2027 targets $10.42 EPS and $57.70B revenue amid continued product launches.
  • Management outlined three-pillar strategy to defend Dupixent against competition; plans to divest Brazilian generics unit Medley as part of portfolio optimization.
Last Updated: 2026-04-23, 08:26 a/m
Read Full Transcript

FAQ

What Is Sanofi ADR's Earnings Per Share (TTM)?

The Sanofi ADR EPS (TTM) is 4.03.

When Is The Next Sanofi ADR Earnings Date?

Sanofi ADR will release its next earnings report on Jul 30, 2026.

What Is Sanofi ADR’s Revenue Forecasts For Upcoming Quarters?

Sanofi ADR’s revenue forecast is 13.17B.

How Did Sanofi ADR React to the Company's Latest Earnings Report?

Sanofi ADR reported a +21.23% EPS surprise and a +18.44% revenue surprise, comparing the latest report against analyst forecasts. The stock price changed by -0.26%, reflecting the market's response to the earnings results.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.